Apellis Pharmaceuticals
APLS
APLS
180 hedge funds and large institutions have $2.29B invested in Apellis Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 80 increasing their positions, 51 reducing their positions, and 53 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
12% less funds holding
Funds holding: 204 → 180 (-24)
42% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 53
44% less capital invested
Capital invested by funds: $4.08B → $2.29B (-$1.79B)
Holders
180
Holding in Top 10
5
Calls
$143M
Puts
$145M
Top Buyers
| 1 | +$224M | |
| 2 | +$84.6M | |
| 3 | +$62.8M | |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$61.8M |
| 5 |
State Street
Boston,
Massachusetts
|
+$49.4M |
Top Sellers
| 1 | -$185M | |
| 2 | -$144M | |
| 3 | -$98M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$30.5M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
-$26M |